Psoriatic Disease 10 Years Later

Scarpa, Raffaele; Caso, Francesco; Costa, Luisa; Peluso, Rosario; Puente, Antonio Del; Olivieri, Ignazio

doi:10.3899/jrheum.161402

Cited by 31 publications

(11 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among SpA, psoriatic arthritis (PsA) is characterized for a broad and heterogeneous spectrum of clinical features and courses [58,59]. In some cases, PsA can occur with peripheral enthesitis, particularly Achilles tendinitis, and/or dactylitis [60,61].…”

Section: Spondyloarthritides Working Groupmentioning

confidence: 99%

Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis

Giacomelli

Afeltra

Alunno

et al. 2019

Autoimmunity Reviews

Self Cite

101

View full text Add to dashboard Cite

Autoimmune rheumatic diseases are characterised by an abnormal immune system response, complement activation, cytokines dysregulation and inflammation. In last years, despite many progresses in managing these patients, it has been shown that clinical remission is reached in less than 50% of patients and a personalised and tailored therapeutic approach is still lacking resulting in a significant gap between guidelines and real-world practice. In this context, the need for biomarkers facilitating early diagnosis and profiling those individuals at the highest risk for a poor outcome has become of crucial interest. A biomarker generally refers to a measured characteristic which may be used as an indicator of some biological state or condition. Three different types of medical biomarkers has been suggested: i. mechanistic markers; ii. clinical disease markers; iii. therapeutic markers. A combination of biomarkers from these different groups could be used for an ideal more accurate diagnosis and treatment. However, although a growing body of evidence is focused on improving biomarkers, a significant amount of this information is not integrated on standard clinical care. The overarching aim of this work was to clarify the meaning of specific biomarkers during autoimmune diseases; their possible role in confirming diagnosis, predicting outcome and suggesting specific treatments.

show abstract

Section: Spondyloarthritides Working Groupmentioning

confidence: 99%

Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis

Giacomelli

Afeltra

Alunno

et al. 2019

Autoimmunity Reviews

Self Cite

101

View full text Add to dashboard Cite

show abstract

“…The presence of CVD considerably reduced in both PsA and PsO patients, treated with TNFi. 39,173 Pharmacological characteristics among TNFi may influence their use in different clinical pictures. 39 TNFi use, in particular of monoclonal antibodies, is also suggested when patients present uveitis or gastrointestinal involvement due to their efficacy and mechanism of action in these pathologies.…”

Section: Discussionmentioning

confidence: 99%

<p>An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis</p>

Chimenti¹,

D’Antonio²,

Conigliaro³

et al. 2020

BTT

Self Cite

View full text Add to dashboard Cite

Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy typically associated with psoriasis (PsO). The pathogenesis is strictly related to the association among the presence of genetic risk alleles and innate and acquired immune response with dramatic consequences on bone remodeling. Clinically, PsA patients may present heterogenicity of articular and periarticular manifestations that may be associated with the presence of comorbidities making treatment decision challenging in patients management. The identification of patient-targeted therapies is still a critical issue. Actually, several biological and synthetic drugs are promising in terms of efficacy and safety profile. National and international treatment recommendations support clinicians in the decision of the best treatment, although they may have limits basically related to updates and different outcomes included in the clinical studies evaluated. The aim of this narrative review is therefore to give guidance for clinicians for PsA patients treatment. For this purpose, we evaluated evidence on biological therapies efficacy used for PsA treatment. Specifically, we reviewed data on biological therapies, Janus kinases (JAK) inhibitors, and drugs with a new mechanism of action that are part of the treatment pipeline. The concept of "switching" and "swapping" is also described, as well as data concerning special populations such as pregnant women and elderly patients.

show abstract

“…In the last years, several studies have described PsA as a systemic condition and ocular involvement has been reported as a possible related manifestation [5].…”

Section: Introductionmentioning

confidence: 99%

A Multimodal Eye Assessment in Psoriatic Arthritis Patients sine-Psoriasis: Evidence for a Potential Association with Systemic Inflammation

Chimenti

Triggianese

Salandri

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

Background: Ocular involvement in Psoriatic Arthritis (PsA) patients is mainly associated with uveitis but there remains a paucity of data on dry eye and retinal abnormalities. We aimed to analyze dry eye and subclinical retinal abnormalities in a cohort of PsA patients sine-psoriasis (PsO). Methods: PsA patients sine-PsO were enrolled. Best-corrected-visual-acuity, ocular-surface-disease-index (OSDI), Schirmer test, tear film breakup-time, standard-automated-perimetry (SAP, mean deviation—MD, pattern standard deviation—PSD), fundus-perimetry (FP), and spectral-domain-optical-coherence-tomography (SD-OCT) were performed. Results: A total of 80 eyes from 40 PsA patients with moderate-severe disease activity, and 70 eyes from 35 healthy control (HC) were evaluated. Higher dry eye prevalence occurred in PsA than HC (p < 0.0001). ESR was positively related with OSDI (p < 0.001) and negatively related with Schirmer (p = 0.007). In PsA, SAP registered higher MD (p < 0.0001) and higher PSD (p = 0.005) in comparison with HC. PSD resulted positively correlated with ESR (p = 0.04) and CRP (p = 0.01), while MD showed a negative correlation with CRP (p = 0.01). Both FP mean differential sensitivity and mean defect were lower in PsA then HC (p < 0.0001). In PsA, FP differential sensitivity was directly related with cumulative steroids (p = 0.02). Conclusions: In PsA patients sine-PsO, dry eye and subclinical abnormalities in visual functions occurred being potentially related to systemic inflammation.

show abstract

Psoriatic Disease 10 Years Later

Cited by 31 publications

References 36 publications

Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis

Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis

<p>An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis</p>

A Multimodal Eye Assessment in Psoriatic Arthritis Patients sine-Psoriasis: Evidence for a Potential Association with Systemic Inflammation

Contact Info

Product

Resources

About